BACKGROUND: The association between human papillomavirus (HPV) infection and the risk of human immunodeficiency virus (HIV) seroconversion is unclear, and the genital cellular immunology has not been evaluated. METHODS: A case-control analysis nested within a male circumcision trial was conducted. Cases consisted of 44 male HIV seroconverters, and controls were 787 males who were persistently negative for HIV. The Roche HPV Linear Array Genotype Test detected high-risk HPV (HR-HPV) and low-risk HPV (LR-HPV) genotypes. Generalized estimating equations logistic regression was used to estimate adjusted odds ratios (aORs) of HIV seroconversion. In addition, densities of CD1a(+) dendritic cells, CD4(+) T cells, and CD8(+) T cells were measured using immunohistochemistry analysis in foreskins of 79 males randomly selected from participants in the circumcision trial. RESULTS: HR-HPV or LR-HPV acquisition was not significantly associated with HIV seroconversion, after adjustment for sexual behaviors. However, HR-HPV and LR-HPV clearance was significantly associated with HIV seroconversion (aOR, 3.25 [95% confidence interval {CI}, 1.11-9.55] and 3.18 [95% CI, 1.14-8.90], respectively). The odds of HIV seroconversion increased with increasing number of HPV genotypes cleared (P < .001, by the test for trend). The median CD1a(+) dendritic cell density in the foreskin epidermis was significantly higher among males who cleared HPV (72.0 cells/mm(2) [interquartile range {IQR}, 29.4-138.3 cells/mm(2)]), compared with males who were persistently negative for HPV (32.1 cells/mm(2) [IQR, 3.1-96.2 cells/mm(2)]; P = .047), and increased progressively with the number of HPV genotypes cleared (P = .05). CONCLUSIONS: HPV clearance was associated with subsequent HIV seroconversion and also with increased epidermal dendritic cell density, which potentially mediates HIV seroconversion.
BACKGROUND: The association between human papillomavirus (HPV) infection and the risk of human immunodeficiency virus (HIV) seroconversion is unclear, and the genital cellular immunology has not been evaluated. METHODS: A case-control analysis nested within a male circumcision trial was conducted. Cases consisted of 44 male HIV seroconverters, and controls were 787 males who were persistently negative for HIV. The Roche HPV Linear Array Genotype Test detected high-risk HPV (HR-HPV) and low-risk HPV (LR-HPV) genotypes. Generalized estimating equations logistic regression was used to estimate adjusted odds ratios (aORs) of HIV seroconversion. In addition, densities of CD1a(+) dendritic cells, CD4(+) T cells, and CD8(+) T cells were measured using immunohistochemistry analysis in foreskins of 79 males randomly selected from participants in the circumcision trial. RESULTS:HR-HPV or LR-HPV acquisition was not significantly associated with HIV seroconversion, after adjustment for sexual behaviors. However, HR-HPV and LR-HPV clearance was significantly associated with HIV seroconversion (aOR, 3.25 [95% confidence interval {CI}, 1.11-9.55] and 3.18 [95% CI, 1.14-8.90], respectively). The odds of HIV seroconversion increased with increasing number of HPV genotypes cleared (P < .001, by the test for trend). The median CD1a(+) dendritic cell density in the foreskin epidermis was significantly higher among males who cleared HPV (72.0 cells/mm(2) [interquartile range {IQR}, 29.4-138.3 cells/mm(2)]), compared with males who were persistently negative for HPV (32.1 cells/mm(2) [IQR, 3.1-96.2 cells/mm(2)]; P = .047), and increased progressively with the number of HPV genotypes cleared (P = .05). CONCLUSIONS:HPV clearance was associated with subsequent HIV seroconversion and also with increased epidermal dendritic cell density, which potentially mediates HIV seroconversion.
Authors: Jordyn L Gamiel; Aaron A R Tobian; Oliver B Laeyendecker; Steven J Reynolds; Rhoda Ashley Morrow; David Serwadda; Ronald H Gray; Thomas C Quinn Journal: Clin Vaccine Immunol Date: 2008-03-05
Authors: Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Zizipho Z A Mbulawa; David Coetzee; Dianne J Marais; Mercy Kamupira; Eugene Zwane; Bruce Allan; Deborah Constant; Jennifer R Moodley; Margaret Hoffman; Anna-Lise Williamson Journal: J Infect Dis Date: 2009-05-15 Impact factor: 5.226
Authors: Aaron A R Tobian; Blake Charvat; Victor Ssempijja; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Boaz Iga; Oliver Laeyendecker; Melissa Riedesel; Amy Oliver; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray; Thomas C Quinn Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Aaron A R Tobian; David Serwadda; Thomas C Quinn; Godfrey Kigozi; Patti E Gravitt; Oliver Laeyendecker; Blake Charvat; Victor Ssempijja; Melissa Riedesel; Amy E Oliver; Rebecca G Nowak; Lawrence H Moulton; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray Journal: N Engl J Med Date: 2009-03-26 Impact factor: 91.245
Authors: Aaron A R Tobian; Victor Ssempijja; Godfrey Kigozi; Amy E Oliver; David Serwadda; Frederick Makumbi; Frederick K Nalugoda; Boaz Iga; Steven J Reynolds; Maria J Wawer; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2009-07-31 Impact factor: 4.177
Authors: Kristine E Johnson; Mark E Sherman; Victor Ssempiija; Aaron A R Tobian; Jonathan M Zenilman; Maire A Duggan; Godfrey Kigozi; David Serwadda; Maria J Wawer; Thomas C Quinn; Charles S Rabkin; Ronald H Gray Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Jia Zhu; Florian Hladik; Amanda Woodward; Alexis Klock; Tao Peng; Christine Johnston; Michael Remington; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: Nat Med Date: 2009-08-02 Impact factor: 53.440
Authors: Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: J Infect Date: 2015-10-19 Impact factor: 6.072
Authors: Mary K Grabowski; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Stephen Watya; Thomas C Quinn; Aaron A R Tobian Journal: Sex Transm Infect Date: 2014-01-30 Impact factor: 3.519
Authors: Rupert Kaul; Cindy M Liu; Daniel E Park; Ronald M Galiwango; Aaron A R Tobian; Jessica L Prodger Journal: Viruses Date: 2022-05-27 Impact factor: 5.818
Authors: Mary K Grabowski; Xiangrong Kong; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Andrew D Redd; Stephen Watya; Thomas C Quinn; Aaron A R Tobian Journal: J Infect Dis Date: 2015-11-23 Impact factor: 5.226
Authors: Anne F Rositch; Lu Mao; Michael G Hudgens; Stephen Moses; Kawango Agot; Danielle M Backes; Edith Nyagaya; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith Journal: AIDS Date: 2014-03-13 Impact factor: 4.177
Authors: Jeffrey Pudney; Zoon Wangu; Lori Panther; Dana Fugelso; Jai G Marathe; Manish Sagar; Joseph A Politch; Deborah J Anderson Journal: J Infect Dis Date: 2019-01-07 Impact factor: 7.759
Authors: Staci L Sudenga; Sarah C Lotspeich; Alan G Nyitray; Bradley Sirak; Bryan E Shepherd; Jane Messina; Karen A Sereday; Roberto Carvalho Silva; Martha Abrahamsen; Maria Luiza Baggio; Manuel Quiterio; Eduardo Lazcano-Ponce; Luisa Villa; Anna R Giuliano Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 3.868